An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...
Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Compass Therapeutics, Inc.’s CMPX share price has dipped by 24.55%, which has investors questioning if this is right time to ...
Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important ...
Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside ...
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
News-Medical.Net on MSN2h
Blocking an enzyme to overcome immunotherapy resistance in melanoma patientsAbout 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...
Because the trial ended up being underpowered, it did not show a benefit of intensive medical treatment, but there was a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback